persicapharma
19
Aug
First stage of PP353 clinical trial completed
Persica Pharmaceuticals has completed the first stage of its clinical trial on a unique injectable, PP353, to treat chronic lower back Novel approach applicable to 20% of all cLBP populations First therapy to directly address a cause of cLBP in Modic 1 subgroup of patients Uniquely for a First in Human cLBP trial there is already clinical proof of concept